首頁 › 慢性淋巴性白血病 › 俄亥俄州 › Cincinnati
Cincinnati, OH 的 慢性淋巴性白血病 臨床試驗
14 項針對 慢性淋巴性白血病 的研究正在 Cincinnati（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- 還有 3 項
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Oncology Hematology Care Clinical Trials, Llc, Cincinnati
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
招募中3 期
- Saint Elizabeth Healthcare ( Site 0041), Edgewood · 距離 8 英里
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
招募中4 期
- Oncology Hematology Care Inc, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- University of Cincinnati Medical Center, Cincinnati
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- University of Cincinnati, Cincinnati
- Oncology Hematology Care, Fairfield · 距離 15 英里
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
招募中1 期
- University of Cincinnati, Cincinnati
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- University of Cincinnati Medical Center, Cincinnati
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
招募中2 期
- Saint Elizabeth Medical Center Edgewood, Edgewood · 距離 8 英里
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
招募中2 期
- University of Cincinnati, Cincinnati
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
招募中2 期
- University of Cincinnati, Cincinnati
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
招募中2 期
- University of Cincinnati Medical Center, Cincinnati
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- University of Cincinnati, Cincinnati
其他城市的 慢性淋巴性白血病 試驗
- Boston, MA31 項研究
- Columbus, OH28 項研究
- Durham, NC27 項研究
- Washington, DC22 項研究
- Seattle, WA20 項研究
- Rochester, MN19 項研究
- New York City, NY18 項研究
- Houston, TX17 項研究
- Baldwin Park, CA16 項研究
- Milwaukee, WI15 項研究
- Chicago, IL14 項研究
- Nashville, TN13 項研究
Cincinnati 的其他研究
- 非小細胞肺癌35 項研究
- 癌症（所有類型）27 項研究
- 乳癌25 項研究
- 心臟衰竭24 項研究
- 大腸直腸癌21 項研究
- 急性髓系白血病20 項研究
- 轉移性癌症20 項研究
- 卵巢癌19 項研究
- 肺癌19 項研究
- 肥胖症19 項研究
- 前列腺癌18 項研究
- 多發性骨髓瘤17 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。